Consejo Nacional de Salud

390
11 White D J, Paul N, Macdonald A, Meyer R M,
Shepherd L E, Addition of lenalidomide to melphalan
in the treatment of newly diagnosed multiple
myeloma: the National Cancer Institute of
Canada Clinical Trials Group MY.11 trial, Current
Oncology—Volume 14, Number 2
12 GullboJ, Lindhagen E, Bashir-Hassan S, Tullberg
M, Ehrsson H, Lewensohn R, Nygren P, de la
Torre M, Luthman K, Larsson R, Antitumor efficacy
and acute toxicity of the novel dipeptide melphalanyl-p-L-fluorophenylalanine
ethyl ester (J1)
in vivo, Investigational New Drugs 22: 411–420,
2004. 411
13 Hasan J, Jayson GC, Oral melphalan as a treatment
for platinum-resistant ovarian cancer, British
Journal of Cancer (2003) 88, 1828 – 1830
14 Kawai, K., Paclitaxel, Ifisfamide and Cisplatin
Regimen is Feasible for Japanese Patients with Advanced
Germ Cell Cancer. [Japan]: Japanese Journal
of Clinical Oncology. Oxford: March, 2003. Vol.
33, Iss. 3; p. 127. Disponible en WWW: http://proquest.umi.com
[Consulta: 19, Noviembre 2008].
15 Vencata, S. Treatment outcome and cost-effectiveness
analysis of two chemotherapeutic regimens
(BEP vs. VIP) for poor-prognosis metastatic
germ cell tumors. [Bangalore-India]: KMIO,
Journal of Cancer, December 2004. Disponible
en WWW: http://cancerjournal.net [Consulta:
15, Noviembre 2008].
16 Stupp, R. Radiotherapy plus Concomitant and Adjuvant
Temozolomide for Glioblastoma. N Engl J
Med 352:987, March, 2005. Disponible en WWW:
http://search.nejm.org/search?w=Radiotherapy+
plus+Concomitant+and+Adjuvant+Temozolomide
+for+Glioblastoma [Consulta: 17, Noviembre 2008
17 Schadendorf, D. Dacarbazine (DTIC) versus vaccination
with autologous peptide-pulsed dendritic
cells (DC) in first-line treatment of patients with
metastatic melanoma. [Germany]: Ann Oncol,
April 2006;17(4):539-41. Disponible en: http://
www.ncbi.nlm.nih.gov/sites/entrez [Consulta: 18,
Noviembre 2008].
18 Martin, M. Biochemotherapy Of Metastatic
Melanoma In Patients With Or Without Recently
Diagnosed Brain Metastases. [Utah]: Wiley Interscience,
May 2007. Disponible En: Http://Www.
Interscience.Wiley.Com/Journal [Consulta: 17,
Noviembre 2008].
19 Boleti, E. Abvd For Hodgkin’s Lymphoma: Full-
Dose Chemotherapy Without Dose Reductions
Or Growth Factors. [Uk]: Ann Oncol. February,
2007;18(2):376-80. Disponible En: Http://
Annonc.Oxfordjournals.Org/Cgi/Content/
Full/18/2/376 [Consulta: 17, Noviembre 2008].
20 Diehl, V. Standard And Increased-Dose Beacopp
Chemotherapy Compared With Copp-Abvdfor
Advanced Hodgkin’s Disease. [Germany]: N Engl J
Med 348:2386, June, 2003. Disponible En: Http://
Nejm.Org [Consulta: 19, Noviembre 2008].
21 Engert, Franklin J, Theodor Eich H, Brillant C,
Sehlen S, Cartoni C, Herrmann R, Pfreundschuh
M, Sieber M, Tesch H, Franke, A, Koch P, de Wit
M, Paulus U, Hasenclever D, Loeffler M, Mu¨ller
R-P, Konrad Mu¨ller-Hermelink H, Du¨hmke H,
Diehl V, Two Cycles of Doxorubicin, Bleomycin,
Vinblastine, and Dacarbazine Plus Extended-
Field Radiotherapy Is Superior to Radiotherapy
Alone in Early Favorable Hodgkin’s Lymphoma:
Final Results of the GHSG HD7 Trial, J Clin Oncol
25:3495-3502